Seaport Therapeutics, Inc. (NASDAQ:SPTX - Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $26.47 and last traded at $25.38, with a volume of 4329 shares traded. The stock had previously closed at $24.31.

Analysts Set New Price Targets

SPTX has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Seaport Therapeutics in a report on Thursday. Wolfe Research initiated coverage on shares of Seaport Therapeutics in a report on Tuesday, July 7th. They issued a "hold" rating for the company. Citigroup assumed coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They set a "buy" rating and a $35.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They issued an "overweight" rating and a $42.00 target price on the stock. Finally, UBS Group downgraded Seaport Therapeutics to a "sell" rating in a research note on Tuesday, June 9th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $38.40.

View Our Latest Analysis on Seaport Therapeutics

Seaport Therapeutics Price Performance

The business has a 50-day simple moving average of $21.04. The company has a market capitalization of $1.27 billion and a PE ratio of -1.95.

Seaport Therapeutics (NASDAQ:SPTX - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($1.07). On average, analysts anticipate that Seaport Therapeutics, Inc. will post -4.6 EPS for the current fiscal year.

Insider Transactions at Seaport Therapeutics

In other news, Director Robert J. Hombach bought 13,000 shares of Seaport Therapeutics stock in a transaction on Monday, June 22nd. The stock was purchased at an average cost of $18.14 per share, with a total value of $235,820.00. Following the purchase, the director directly owned 13,000 shares of the company's stock, valued at approximately $235,820. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Institutional Investors Weigh In On Seaport Therapeutics

A number of hedge funds have recently made changes to their positions in SPTX. TRV GP VI LLC bought a new position in Seaport Therapeutics in the 2nd quarter worth approximately $44,769,742,000. Braidwell LP bought a new stake in Seaport Therapeutics during the 2nd quarter valued at $10,860,000. Finally, Alyeska Investment Group L.P. bought a new stake in Seaport Therapeutics during the 2nd quarter valued at $1,629,000.

About Seaport Therapeutics

(Get Free Report)

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.

Read More

• Five stocks we like better than Seaport Therapeutics
• If Boeing Ramps Up Production, These Suppliers May Win Big
• Marvell Takes a Shot a Broadcom's Throne With Google Deal
• 5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here's Why
• Aehr Test Systems Soars Again on Latest Orders, Jefferies Eyes Big-Time Upside Ahead

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Seaport Therapeutics Right Now?

Before you consider Seaport Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seaport Therapeutics wasn't on the list.

While Seaport Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here